CDKN2A and neoplasm: Eight (16%) of the 50 tumours with available CDKN2A/B data demonstrated homozygous deletion; while these patients had slightly shorter survival (HR 1.37), the difference was not statistically significant (95% CI 0.41–2.08, p=0.571).